Cargando…
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer
BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response classification (WHO; based on XR and SS) in stratifying b...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837571/ https://www.ncbi.nlm.nih.gov/pubmed/20104228 http://dx.doi.org/10.1038/sj.bjc.6605546 |
_version_ | 1782178825873915904 |
---|---|
author | Hamaoka, T Costelloe, C M Madewell, J E Liu, P Berry, D A Islam, R Theriault, R L Hortobagyi, G N Ueno, N T |
author_facet | Hamaoka, T Costelloe, C M Madewell, J E Liu, P Berry, D A Islam, R Theriault, R L Hortobagyi, G N Ueno, N T |
author_sort | Hamaoka, T |
collection | PubMed |
description | BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response classification (WHO; based on XR and SS) in stratifying breast cancer patients with bone-only metastases with respect to progression-free survival (PFS), overall survival (OS), and clinical response. METHODS: We retrospectively reviewed 41 patients with bone-only metastatic breast cancer and assigned responses according to the MDA and WHO criteria. We analysed whether the MDA or WHO response classifications correlated with PFS and OS. RESULTS: With the MDA criteria, there were significant differences in PFS between patients classified as responders and those classified as nonresponders (P=0.025), but with the WHO criteria, there were not. Neither criteria distinguished responders from nonresponders in terms of OS. MDA response criteria correlated better than WHO response criteria with clinical response assessment. CONCLUSIONS: The MDA classification is superior to the WHO classification in differentiating between responders and nonresponders among breast cancer patients with bone-only metastases. Application of the MDA classification may allow bone lesions to be considered measurable disease. Prospective study is needed to test the MDA classification among patients with bone metastasis. |
format | Text |
id | pubmed-2837571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-28375712011-02-16 Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer Hamaoka, T Costelloe, C M Madewell, J E Liu, P Berry, D A Islam, R Theriault, R L Hortobagyi, G N Ueno, N T Br J Cancer Clinical Study BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response classification (WHO; based on XR and SS) in stratifying breast cancer patients with bone-only metastases with respect to progression-free survival (PFS), overall survival (OS), and clinical response. METHODS: We retrospectively reviewed 41 patients with bone-only metastatic breast cancer and assigned responses according to the MDA and WHO criteria. We analysed whether the MDA or WHO response classifications correlated with PFS and OS. RESULTS: With the MDA criteria, there were significant differences in PFS between patients classified as responders and those classified as nonresponders (P=0.025), but with the WHO criteria, there were not. Neither criteria distinguished responders from nonresponders in terms of OS. MDA response criteria correlated better than WHO response criteria with clinical response assessment. CONCLUSIONS: The MDA classification is superior to the WHO classification in differentiating between responders and nonresponders among breast cancer patients with bone-only metastases. Application of the MDA classification may allow bone lesions to be considered measurable disease. Prospective study is needed to test the MDA classification among patients with bone metastasis. Nature Publishing Group 2010-02-16 2010-01-26 /pmc/articles/PMC2837571/ /pubmed/20104228 http://dx.doi.org/10.1038/sj.bjc.6605546 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Hamaoka, T Costelloe, C M Madewell, J E Liu, P Berry, D A Islam, R Theriault, R L Hortobagyi, G N Ueno, N T Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer |
title | Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer |
title_full | Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer |
title_fullStr | Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer |
title_full_unstemmed | Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer |
title_short | Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer |
title_sort | tumour response interpretation with new tumour response criteria vs the world health organisation criteria in patients with bone-only metastatic breast cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837571/ https://www.ncbi.nlm.nih.gov/pubmed/20104228 http://dx.doi.org/10.1038/sj.bjc.6605546 |
work_keys_str_mv | AT hamaokat tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT costelloecm tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT madewellje tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT liup tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT berryda tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT islamr tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT theriaultrl tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT hortobagyign tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer AT uenont tumourresponseinterpretationwithnewtumourresponsecriteriavstheworldhealthorganisationcriteriainpatientswithboneonlymetastaticbreastcancer |